header logo image

Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update

May 14th, 2024 2:34 am

NEW HOPE, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its first quarter 2024 financial results and provided a business update.

Visit link:
Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update

Related Post

Comments are closed.


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick